We specialize in the sectors where commercial clarity is a valuation lever, not a marketing exercise.
Mid-market healthcare is not a single market. Pharmacy buyers evaluate businesses differently than healthtech acquirers. Women's health companies carry a different burden of proof than longevity companies. AgeTech operates in a different multi-stakeholder buying environment than any of them.
Book a Strategic Fit Call →
In pharmacy, operational strength doesn't automatically translate into buyer confidence.
Pharmacy is one of the most operationally complex sectors in healthcare. Margins are under pressure. Buyers are sophisticated. Scrutiny is high and gets higher as the process advances.
Strong performance isn't enough if the story, proof, and positioning don't match how buyers actually evaluate pharmacy businesses. That gap is where value gets discounted.
Book a Strategic Fit Call →Where growth breaks in pharmacy
Pharmacy buyers evaluate margin durability, contract stability, and transferability. Most sellers aren't ready for those questions.
- The business is performing well but buyers don't fully understand or value what's been built
- Growth happened through relationships and operational excellence, not a structured commercial system
- The story depends too heavily on leadership knowledge or key individual relationships
- Buyers are asking detailed diligence questions that expose gaps in narrative or proof
- Strong financials still prompt cautious questions rather than confident offers
Who this is for
Strong fit
- Mid-market pharmacy companies preparing for growth or exit
- Specialty pharmacy, PBM-aligned, or complex service models
- Leadership teams facing increased buyer or investor scrutiny
- Companies where strong financials aren't producing the buyer confidence the numbers should support
Not a fit
- Early-stage businesses without operational maturity
- Teams looking for marketing execution without strategic alignment
Common questions
Buyers evaluate pharmacy companies based on growth quality, margin durability, contract stability, and operational scalability. They also assess regulatory risk and how dependent the business is on key individuals. A clear, defensible narrative helps buyers understand and trust those factors quickly, which directly impacts valuation. Strong financials with a weak or fragmented narrative consistently produce lower offers than the numbers alone should warrant.
Higher multiples are driven by predictable revenue, strong margins, diversified contracts, and operational scalability. Just as important is how clearly these strengths are communicated. When buyers can quickly understand and validate the business without requiring extensive explanation, perceived risk decreases and valuation improves.
Buyers assess concentration risk, reimbursement pressure, compliance exposure, and reliance on key individuals. They also evaluate whether growth is sustainable or dependent on short-term factors. Unclear or inconsistent narratives amplify every one of these concerns, because ambiguity reads as risk to a sophisticated buyer.
Preparation includes aligning the narrative with how buyers evaluate the business, structuring proof to support the claims being made, and ensuring operations are documented and transferable. Addressing these areas 18 to 36 months before a planned transaction reduces friction during diligence and maximizes the leverage leadership has to influence the offer.
Because buyers don't fully understand the business or see gaps in how it's presented. Even strong financial performance gets discounted when the narrative is unclear, the proof is incomplete, or the business appears dependent on relationships that won't survive the transaction. Clarity and alignment aren't soft factors, they're direct valuation levers.
Ideally 18 to 36 months before a planned exit. Early preparation allows time to strengthen the narrative, align proof, and reduce the risk that diligence surfaces concerns the leadership team didn't anticipate. Companies that wait until the process begins have the least leverage to address the gaps buyers will find.
Healthtech is crowded. Strong products and real outcomes aren't enough to win a premium multiple.
Most healthtech companies we work with aren't struggling to grow. They're struggling to make that growth legible, to buyers who are increasingly risk-sensitive, to boards who want proof not potential, and to investors who've seen too many promising companies get discounted in diligence.
The gap between what the business is producing and what it's worth is where most healthtech enterprise value is lost.
Book a Strategic Fit Call →Where growth breaks in healthtech
Most healthtech companies scale faster than their commercial system can support.
- Buyers become more risk-sensitive as the company grows, they evaluate proof, not potential
- Sales cycles extend to 12 to 24 months with more stakeholders in the room
- Positioning and messaging fragment as the team expands
- Marketing, sales, and product each tell a slightly different story
- The narrative that got the company to $20M starts to break at $75M
Who this is for
Strong fit
- Mid-market healthtech companies with $10M to $250M in revenue
- PE-backed, VC-backed, or founder-led, with an exit or capital event on a 12 to 36 month horizon
- Companies where growth is real but the commercial story isn't consistently landing with buyers and investors
Not a fit
- Early-stage companies still finding product-market fit
- Teams looking for demand generation or campaign execution without strategic alignment
Common questions
Because most describe their product, not their value. Buyers evaluate outcomes, risk, and relevance, not features. Without clear positioning and aligned proof, even strong companies appear interchangeable. Differentiation becomes visible once positioning is structured around how buyers actually evaluate decisions, not around what the internal team is most proud of.
They look for clear differentiation, credible proof, scalable growth, and low dependency on founders or key individuals. They also evaluate how easily the business can be understood and trusted across stakeholders. Companies that make it easy for a buyer to build conviction quickly command significantly higher multiples than those that require interpretation.
By improving commercial clarity, aligning proof with buyer expectations, and ensuring the growth story is consistent and defensible. Valuation increases when buyers can quickly understand and validate the business. The most effective work happens 18 to 36 months before a planned transaction, early enough to close gaps before they're exposed in diligence.
As companies grow, deals involve more stakeholders, higher budgets, and greater scrutiny. Without a clear narrative and aligned proof, decision-making slows and deals are more likely to stall at each stakeholder level. The solution isn't more follow-up, it's a commercial system that gives each decision-maker the clarity and confidence they need to move forward.
Adding more activity instead of fixing positioning and alignment. More campaigns, more tools, and more vendors don't solve unclear differentiation, they typically make it worse by adding noise. Buyers don't reward effort. They reward clarity and confidence. The companies that scale cleanly are the ones that fixed the commercial system first.
Before growth stalls or exit pressure increases. Addressing positioning, proof, and alignment early reduces risk and makes scaling more efficient. The companies that get the highest valuation multiples are the ones that built commercial clarity into the growth process, not the ones that scrambled to assemble it in the last six months before a transaction.
In women's health, what worked early rarely survives the scrutiny that comes with scale.
Many women's health companies find that the momentum that drove early growth, a clear mission, strong outcomes, a passionate market, doesn't translate cleanly when buyers and investors start evaluating the business through a risk lens.
The story has to do more than resonate. It has to hold up under diligence.
Book a Strategic Fit Call →Where growth breaks in women's health
Mission-driven companies often outgrow their commercial narrative before they realize it.
- The value story is compelling internally but doesn't land with enterprise buyers
- Proof exists but isn't structured in a way that reduces buyer risk quickly
- Growth feels fragile or inconsistent as the market evolves
- The narrative leans on mission when buyers are evaluating performance and transferability
- Deals stall late or take longer than they should without a clear reason
Who this is for
Strong fit
- Mid-market women's health companies scaling beyond early traction
- VC-backed or PE-owned, with buyers or investors in view
- Leadership teams where the mission is clear but the commercial story isn't closing deals the way it should
Not a fit
- Early-stage companies still validating demand
- Teams looking for execution-only marketing or brand work
Common questions
Demand alone doesn't drive scale. Buyers evaluate risk, proof, and transferability. Many women's health companies have strong outcomes but lack a clear, defensible narrative that translates to enterprise buyers. That gap slows growth, because the company is still educating the market while buyers are already evaluating whether the business is acquisition-ready.
They look for clarity, credible proof, and repeatable growth. They evaluate whether positioning is defensible, whether outcomes are supported by evidence buyers trust, and whether the business can scale without heavy founder dependence. Mission resonates early. At exit, buyers want proof that the mission is backed by durable commercial infrastructure.
By strengthening narrative clarity, aligning proof with buyer expectations, and ensuring growth systems are consistent and transferable. Valuation improves when buyers can understand and defend the story quickly, to their own investment committees, boards, and partners. That requires commercial work, not more mission-driven content.
Early traction is typically driven by mission and innovation appeal. Later-stage buyers require clearer evidence and less ambiguity. If messaging doesn't evolve to match how buyers at that stage evaluate risk, it creates friction and slows decisions. The narrative that earned early adopters often doesn't earn acquirers, and the gap between the two is where deals stall.
It often involves market education, multiple stakeholders with different risk sensitivities, and heightened scrutiny around outcomes and trust. This increases the burden of proof and requires stronger alignment across narrative, evidence, and GTM motion. Companies that build that alignment early, rather than assembling it under exit pressure, capture significantly more value.
Before growth stalls or exit pressure increases. The leverage to fix commercial gaps is highest when the business is growing, not when it's under scrutiny. Engaging 18 to 36 months before a planned transaction gives leadership the time to strengthen narrative, align proof, and reduce the risk that diligence surfaces concerns the team didn't see coming.
In longevity, credibility is the growth lever. Most companies are managing it wrong.
Longevity is one of the fastest-growing and most scrutinized sectors in healthcare. Buyers and investors evaluate longevity companies through a risk-first lens, and the market is already full of companies that eroded trust by overpromising.
Getting the commercial story right isn't optional here. It's the primary driver of whether growth translates into enterprise value.
Book a Strategic Fit Call →Where growth breaks in longevity
Trust is the gating factor for growth. Inconsistency destroys it faster than competition.
- Science is strong but the value story isn't landing with buyers or investors
- Translating complex data into clear, commercial positioning without oversimplifying is unresolved
- Buyers are interested but hesitant, perceived risk is higher than the evidence warrants
- The category is crowded with bold claims, making credible differentiation harder
- Growth exists, but confidence in how it will hold up under scrutiny is low
Who this is for
Strong fit
- Mid-market longevity companies with real clinical or scientific evidence and a growth story that isn't fully landing
- VC-backed or PE-owned, with investors or acquirers in view
- Leadership teams where credibility is a known challenge, in category perception or in the proof set itself
Not a fit
- Early-stage companies still building an evidence base
- Companies whose challenges are primarily operational or clinical, not commercial
Common questions
Because the market is saturated with overclaiming. Buyers approach longevity companies with heightened skepticism, not because the science is weak, but because so many companies have damaged trust with unsubstantiated claims. The companies that build buyer confidence are the ones that make their evidence legible and their claims defensible, rather than competing on boldness.
They look for credible evidence, clear differentiation, and a commercial system that doesn't depend on the founder to explain the value. They want to see that the business can scale without overpromising, and that the growth story holds up when a skeptical buyer looks closely. Companies that can demonstrate credibility without complexity earn significantly higher confidence and valuation.
By being structurally different from the companies making bold claims. That means grounding positioning in evidence, not aspiration. Structuring proof so buyers can evaluate it without relying on founder explanation. And aligning the commercial narrative consistently across every stakeholder conversation, so the story is the same whether the CEO, the CMO, or the sales team is in the room.
Oversimplification creates a different kind of credibility gap. Buyers sense when a company is describing outcomes that the evidence doesn't fully support, even if the claim sounds reasonable on the surface. The result is a discount for uncertainty. The goal isn't to simplify the science, it's to make the science legible to buyers who don't have PhDs. Those are very different problems.
Before growth starts to feel dependent on relationships or founder credibility rather than the strength of the evidence. The earlier the commercial system is built around proof and positioning, the more durable the growth trajectory becomes. Companies that address this early tend to attract better investors, close better deals, and enter exit processes with significantly less diligence risk.
AgeTech solutions are complex. The commercial story has to be simple enough for every buyer to trust.
Technology evolves quickly in AgeTech. Trust is earned slowly. That gap, between what the solution actually does and what different buyers are willing to believe, is where most AgeTech enterprise value is lost.
Book a Strategic Fit Call →Where growth breaks in age tech
Multi-stakeholder buying environments are only manageable with a unified commercial system.
- Multiple stakeholders influence decisions but the message doesn't land consistently across them
- Solutions are valuable but hard to explain quickly and credibly
- Sales cycles are long with deals stalling at different stakeholder levels
- Growth depends too heavily on individual relationships or founder involvement
- Traction exists but isn't predictable, repeatable, or transferable
Who this is for
Strong fit
- Mid-market AgeTech companies scaling beyond early traction
- B2B or B2B2C models with complex buying groups
- Leadership teams dealing with inconsistent growth, long sales cycles, or fragmented messaging
Not a fit
- Early-stage companies still validating demand
- Teams looking for more sales activity rather than structural alignment
Common questions
Because demand is fragmented. AgeTech solutions often serve multiple stakeholders, families, caregivers, providers, payers, and partners, who each have different priorities, risk concerns, and definitions of value. If positioning and proof don't translate consistently across those groups, growth slows even when need is high. The problem isn't demand. It's that the commercial story isn't built for the buying environment.
Buyers typically include caregivers, families, providers, payers, and enterprise partners. Each evaluates your solution differently and carries different risk sensitivities. Successful AgeTech companies align their narrative and proof across all stakeholder groups rather than customizing endlessly for each one. That alignment is what makes growth predictable and transferable, the two qualities buyers pay a premium for.
Multiple stakeholders increase decision complexity. Each layer introduces additional proof requirements, risk evaluation, and internal alignment. Without a clear, unified narrative, deals take longer to close and are more likely to stall. The companies that shorten cycles don't do it by adding more sales resources, they do it by reducing the friction that comes from inconsistent messaging and proof.
By creating consistent positioning, aligning proof with buyer expectations, and building a GTM system that reduces dependence on individual relationships. Predictability comes from alignment, not more activity. When the commercial system is functioning, each customer win reinforces the next rather than requiring the same level of effort to close.
They look for scalable growth, not just strong demand. That includes clear positioning, a repeatable sales motion, credible proof across stakeholder groups, and reduced founder dependence. Fragmented narratives or growth that can't be explained without the founder in the room reduce investor confidence and valuation.
As soon as growth starts to feel inconsistent or overly dependent on individuals. Addressing narrative, proof, and alignment early makes scaling easier and reduces risk during future investment or acquisition. The companies that wait until exit pressure is visible have the fewest options to close the gaps that buyers will find.
What Legacy DNA does
Legacy DNA builds the commercial system that closes the gap between what your business is producing and what it's actually worth. The Enterprise Value Creation System™ is the framework we use — a six-stage model that maps where alignment is breaking and what to fix, in the order that creates the most leverage.
This is not strategy consulting or agency work. We operate inside the business to build the system. The work is senior-led by Dr. Roxie Mooney and designed to hold up in board presentations, investor conversations, and diligence rooms.
